Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
- PMID: 15711732
- DOI: 10.1160/TH04-09-0580
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
Abstract
The urokinase-mediated plasminogen activation (PA) system is involved in many physiological and pathological events that include cell migration and tissue remodelling, such as embryogenesis, ovulation, inflammation, wound healing, angiogenesis, and tumor invasion and metastasis. The urokinase receptor (uPAR) is a key molecule of this system and can bind extracellular and cell membrane molecules such as urokinase (uPA), vitronectin (VN), integrins and chemotaxis receptors. These multiple interactions can be modulated by the shedding or the cleavage of the cell membrane receptor. Indeed, cleaved forms of uPAR, lacking the N-terminal D1 domain, have been detected on the surface of cells and in tissues, while soluble forms have been found in biological fluids. Cleaved and soluble forms could represent the intermediary products of the uPAR metabolism or active molecules with precise and distinct functional roles. Here, we review the data concerning the in vitro and in vivo identification of these uPAR forms, their origin and functions, and the role that uPAR shedding and cleavage could play in biological processes.
Comment in
-
Proteases and extracellular environment.Thromb Haemost. 2005 Feb;93(2):190-1. Thromb Haemost. 2005. PMID: 15711731 No abstract available.
Similar articles
-
Urokinase receptor variants in tissue and body fluids.Adv Clin Chem. 2007;44:65-102. Adv Clin Chem. 2007. PMID: 17682340 Review.
-
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150. Biol Chem. 2001. PMID: 11592401
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
-
The cleavage of the urokinase receptor regulates its multiple functions.J Biol Chem. 2002 Dec 6;277(49):46932-9. doi: 10.1074/jbc.M207494200. Epub 2002 Sep 23. J Biol Chem. 2002. PMID: 12297505
-
Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.Front Biosci. 2008 May 1;13:6752-62. doi: 10.2741/3186. Front Biosci. 2008. PMID: 18508692 Review.
Cited by
-
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376. Cancers (Basel). 2021. PMID: 34771541 Free PMC article. Review.
-
Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).Mol Cell Biochem. 2009 Jan;321(1-2):111-22. doi: 10.1007/s11010-008-9925-z. Epub 2008 Oct 2. Mol Cell Biochem. 2009. PMID: 18830568
-
Crystal structure and cellular functions of uPAR dimer.Nat Commun. 2022 Mar 29;13(1):1665. doi: 10.1038/s41467-022-29344-y. Nat Commun. 2022. PMID: 35351875 Free PMC article.
-
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.Int J Mol Sci. 2017 Jul 31;18(8):1662. doi: 10.3390/ijms18081662. Int J Mol Sci. 2017. PMID: 28758975 Free PMC article. Clinical Trial.
-
Role of urokinase receptor in tumor progression and development.Theranostics. 2013 Jun 25;3(7):487-95. doi: 10.7150/thno.4218. Print 2013. Theranostics. 2013. PMID: 23843896 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous